LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Inicio・Lista de Acciones・Heron Therapeutics Inc

Heron Therapeutics Inc

Cerrado

SectorSanidad

1.21 -0.82

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.2

Máximo

1.22

Métricas clave
By Trading Economics
Ingresos	15M -3M
Ventas	2.4M 41M
BPA	-0.02
Margen de beneficios	-7.278
Empleados	128
EBITDA	13M -792K

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+271.9% upside

Dividendos
By Dow Jones
Próximas Ganancias	11 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	12M 230M
Apertura anterior	2.03
Cierre anterior	1.21

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

2.0001 / 2.42 Soporte y Resistencia

Heron Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 may 2026, 23:47 UTC

Charlas de Mercado

Gold Falls on Renewed Inflation Concerns -- Market Talk

10 may 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10 may 2026, 23:38 UTC

Charlas de Mercado

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10 may 2026, 23:14 UTC

Charlas de Mercado

Australia's Political Map Continues to Be Redrawn -- Market Talk

10 may 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

Elevra Lithium: Expects Deal to Close in 1Q FY27

10 may 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10 may 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10 may 2026, 10:21 UTC

Ganancias

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9 may 2026, 06:05 UTC

Ganancias

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 may 2026, 23:55 UTC

Ganancias

Review & Preview: Still Going Strong -- Barrons.com

8 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 may 2026, 20:49 UTC

Ganancias

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 may 2026, 20:25 UTC

Ganancias

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 may 2026, 19:43 UTC

Ganancias

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 may 2026, 19:43 UTC

Ganancias

Cencosud 1Q Net $115M

8 may 2026, 19:20 UTC

Charlas de Mercado

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 may 2026, 19:18 UTC

Ganancias

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 may 2026, 19:16 UTC

Ganancias

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 may 2026, 19:08 UTC

Ganancias

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 may 2026, 19:05 UTC

Ganancias

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 may 2026, 19:02 UTC

Charlas de Mercado

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 may 2026, 18:51 UTC

Ganancias

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 may 2026, 18:49 UTC

Ganancias

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 may 2026, 18:41 UTC

Ganancias

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 may 2026, 17:38 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 may 2026, 17:14 UTC

Ganancias

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 may 2026, 17:04 UTC

Charlas de Mercado

Zcash Caps Off Parabolic Week -- Market Talk

8 may 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 may 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 may 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Heron Therapeutics Inc previsión

Precio Objetivo

By TipRanks

271.9% repunte

Estimación a 12 Meses

Media 4.5 USD 271.9%

Máximo 6 USD

Mínimo 3 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Heron Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Heron Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

2.0001 / 2.42Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.